Proteostasis Therapeutics, Inc. (PTI) financial statements (2021 and earlier)

Company profile

Business Address 40 GUEST STREET
BOSTON, MA 02135
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:81701187586
Cash and cash equivalents8125293019
Short-term investments 44904567
Other undisclosed cash, cash equivalents, and short-term investments 000(0)
Restricted cash and investments   0 
Receivables    1
Prepaid expense 0000
Other undisclosed current assets71214
Total current assets:88711217690
Noncurrent Assets
Finance lease, right-of-use asset0 
Operating lease, right-of-use asset2413
Property, plant and equipment101171
Restricted cash and investments21120
Other noncurrent assets   00
Other undisclosed noncurrent assets0 14  
Total noncurrent assets:271415181
TOTAL ASSETS:115851369491
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities159886
Accounts payable72222
Accrued liabilities87664
Deferred revenue8 
Debt31   
Deferred revenue and credits12
Other liabilities   1 
Other undisclosed current liabilities4 1  
Total current liabilities:31109109
Noncurrent Liabilities
Long-term debt and lease obligation2812   
Long-term debt, excluding current maturities13    
Finance lease, liability0 
Operating lease, liability1412
Liabilities, other than long-term debt 00151
Deferred revenue and credits 1
Other liabilities   15 
Derivative instruments and hedges, liabilities 0000
Other undisclosed noncurrent liabilities(14) 13  
Total noncurrent liabilities:281213151
Total liabilities:5922222610
Stockholders' equity
Stockholders' equity attributable to parent56621146981
Common stock00000
Additional paid in capital204399392286239
Accumulated other comprehensive income (loss) 00(0)(0)
Accumulated deficit(148)(337)(278)(217)(157)
Total stockholders' equity:56621146981
TOTAL LIABILITIES AND EQUITY:115851369491

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Gross profit:75358
Operating expenses(63)(66)(66)(65)(46)
Operating loss:(56)(61)(63)(60)(37)
Nonoperating income (expense)(2)2110
Investment income, nonoperating 1110
Other nonoperating income (expense) 10(0)(0)
Interest and debt expense(2)    
Loss before gain (loss) on sale of properties:(59)(59)(62)(59)(37)
Other undisclosed net income2    
Net loss attributable to parent:(57)(59)(62)(59)(37)
Preferred stock dividends and other adjustments    (1)
Other undisclosed net income available to common stockholders, basic7    
Net loss available to common stockholders, diluted:(51)(59)(62)(59)(39)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(57)(59)(62)(59)(37)
Comprehensive loss:(57)(59)(62)(59)(37)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 000(0)
Comprehensive loss, net of tax, attributable to parent:(57)(59)(62)(59)(37)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: